List of BTK inhibitors (Bruton Tyrosine Kinase Inhibitor) - Drugs.com
2023年4月12日 · Ibrutinib was the first BTK inhibitor approved in 2013, but subsequent BTK inhibitors are associated with fewer side effects. Ibrutinib is associated with a high risk of bleeding (approximately 50% of patients develop minor bleeding), atrial fibrillation (16% of patients), and high blood pressure (almost 40% of patients with CLL taking ...
What are the names of the BTK inhibitors? - Drugs.com
2013年11月13日 · Mantle Cell Lymphoma (MCL) who have received at least two prior therapies, including a BTK inhibitor. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Zanubrutinib: Uses, Dosage, Side Effects, Warnings - Drugs.com
2024年3月12日 · Zanubrutinib belongs to a class of drugs called kinase inhibitors. Zanubrutinib is a second-generation irreversible BTK (Bruton tyrosine kinase) inhibitor that works by blocking the action of a protein called Bruton's tyrosine kinase, which signals B-cells to grow and multiply. This stops cancer from growing in your body.
Jaypirca: Uses, Dosage, Side Effects, Warnings - Drugs.com
2024年6月24日 · Jaypirca tablet is an oral kinase inhibitor, and more specifically, it is a non-covalent (reversible) BTK inhibitor. How does Jaypirca work? Jaypirca's mechanism of action (MOA) is that it blocks BTK, which is a signaling protein found across numerous B-cell leukemia and lymphomas, including MCL, CLL, and SLL, that, when stimulated, activates ...
Pirtobrutinib: Uses, Dosage, Side Effects, Warnings - Drugs.com
2024年5月2日 · Relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of treatment, including a BTK inhibitor; Chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two lines of treatment, including a Bruton's tyrosine kinase (BTK) inhibitor and a BCL-2 inhibitor. Pirtobrutinib side effects
Brukinsa: Uses, Dosage, Side Effects, Warnings - Drugs.com
2024年6月23日 · Brukinsa directly inhibits an enzyme, called Bruton’s tyrosine kinase (BTK), by forming a covalent bond with a cysteine residue on the enzyme, preventing its activity. BTK works as a signaling molecule for the B-cell antigen receptor (BCR) and cytokine receptor pathways.
Jaypirca (pirtobrutinib) FDA Approval History - Drugs.com
2023年12月18日 · Jaypirca works by binding to BTK to inhibit the activity of BTK kinase (a molecular target found across numerous B-cell leukemias) to block the activity that leads to growth of B-cells, and causes cell death of the malignant B-cells. Jaypirca is the first FDA-approved non-covalent (reversible) BTK inhibitor.
Rilzabrutinib Demonstrated Significant Patient Benefit in the First ...
2024年12月9日 · Rilzabrutinib is an oral, reversible, covalent BTK inhibitor that has the potential to be a first- and best-in-class treatment of several immune-mediated and inflammatory diseases. BTK, expressed in B cells, macrophages, and other immune cells, plays a critical role in inflammatory pathways and multiple immune-mediated disease processes.
Brukinsa Side Effects: Common, Severe, Long Term - Drugs.com
2023年6月21日 · For healthcare professionals. Applies to zanubrutinib: oral capsule. General adverse events. The most common adverse reactions were decreased neutrophil count, upper respiratory tract infection, decreased platelet count, hemorrhage/hematoma, rash, bruising, and musculoskeletal pain.
Ibrutinib: 7 things you should know - Drugs.com
2024年5月20日 · Ibrutinib is an oral BTK inhibitor that may be used to treat several different cancers and graft versus host disease. Ibrutinib is available as the brand Imbruvica. There is no Imbruvica generic. Ibrutinib works by inhibiting the enzyme Bruton tyrosine kinase (BTK).